High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
AbbVie is riding a post-Humira reinvention, while Pfizer is still unwinding its COVID-era identity and searching for a durable growth engine. For dividend investors, the contrast is sharp. Quick Read AbbVie (ABBV) generated $17.82B in free cash flow against $11.66B in dividend payments (1.53x coverage), with Skyrizi reaching $5.01B in Q4 revenue, up 32.5% year-over-year. Pfizer (PFE) reported $17.56B in Q4 revenue but faces dividend sustainability issues with free cash flow of $9.08B covering only 0.93x of $9.77B in dividend payments, forcing reliance on balance sheet borrowing as COVID product revenue collapsed 33% to 70%. AbbVie's blockbuster immunology drugs Skyrizi and Rinvoq are replacing Humira-era revenue while funding dividend growth, whereas Pfizer is racing to scale its non-COVID portfolio and execute $7.2B in cost savings by end-2027 before its unsustainable dividend erodes the balance sheet further. If you're focused on picking the right stocks and ETFs you may b
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- 2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory [Yahoo! Finance]Yahoo! Finance
- 2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- What You Need to Know Ahead of AbbVie's Earnings Release [Yahoo! Finance]Yahoo! Finance
- Assessing AbbVie (ABBV) Valuation After New Dermatology Data And FDA Label Update [Yahoo! Finance]Yahoo! Finance
- Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 4/3/26 - Form 8-K
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- ABBV's page on the SEC website